The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isola... von Conley, A J, Kessler, 2nd, J A, Boots, L J, McKenna, P M, Schleif, W A, Emini, E A, Mark, 3rd, G E, Katinger, H, Cobb, E K, Lunceford, S M, Rouse, S R, Murthy, K K

Volltext

Correlates of protective immunity against HIV-1 infection in immunized chimpanzees von Murthy, Krishna K., Cobb, E.Kathy, Rouse, Scott R., Lunceford, Stacie M., Johnson, Deborah E., Galvan, Annette R.

Volltext

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase... von Seiwert, Tanguy Y, Dr, Burtness, Barbara, MD, Mehra, Ranee, Weiss, Jared, MD, Berger, Raanan, MD, Eder, Joseph Paul, MD, Heath, Karl, MPH, McClanahan, Terrill, PhD, Lunceford, Jared, PhD, Gause, Christine, PhD, Cheng, Jonathan D, MD, Chow, Laura Q, MD

Volltext

Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study von Lunceford, Jared K., Davidian, Marie

Volltext

PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer von Yearley, Jennifer H, Gibson, Christopher, Yu, Ni, Moon, Christina, Murphy, Erin, Juco, Jonathan, Lunceford, Jared, Cheng, Jonathan, Chow, Laura Q M, Seiwert, Tanguy Y, Handa, Masahisa, Tomassini, Joanne E, McClanahan, Terrill

Volltext

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma von Daud, Adil I, Wolchok, Jedd D, Robert, Caroline, Hwu, Wen-Jen, Weber, Jeffrey S, Ribas, Antoni, Hodi, F Stephen, Joshua, Anthony M, Kefford, Richard, Hersey, Peter, Joseph, Richard, Gangadhar, Tara C, Dronca, Roxana, Patnaik, Amita, Zarour, Hassane, Roach, Charlotte, Toland, Grant, Lunceford, Jared K, Li, Xiaoyun Nicole, Emancipator, Kenneth, Dolled-Filhart, Marisa, Kang, S Peter, Ebbinghaus, Scot, Hamid, Omid

Volltext

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial von Muro, Kei, Dr, Chung, Hyun Cheol, Prof, Shankaran, Veena, MD, Geva, Ravit, MD, Catenacci, Daniel, MD, Gupta, Shilpa, MD, Eder, Joseph Paul, MD, Golan, Talia, MD, Le, Dung T, MD, Burtness, Barbara, MD, McRee, Autumn J, MD, Lin, Chia-Chi, MD, Pathiraja, Kumudu, MA, Lunceford, Jared, PhD, Emancipator, Kenneth, MD, Juco, Jonathan, MD, Koshiji, Minori, MD, Bang, Yung-Jue, Prof

Volltext

T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers... von Ott, Patrick A, Bang, Yung-Jue, Piha-Paul, Sarina A, Razak, Albiruni R Abdul, Bennouna, Jaafar, Soria, Jean-Charles, Rugo, Hope S, Cohen, Roger B, O'Neil, Bert H, Mehnert, Janice M, Lopez, Juanita, Doi, Toshihiko, van Brummelen, Emilie M J, Cristescu, Razvan, Yang, Ping, Emancipator, Kenneth, Stein, Karen, Ayers, Mark, Joe, Andrew K, Lunceford, Jared K

Volltext

Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer von Kulangara, Karina, Zhang, Nancy, Corigliano, Ellie, Guerrero, Lindsay, Waldroup, Stephanie, Jaiswal, Dipeshkumar, Ms, Malinka Jansson, Shah, Supriya, Hanks, Debra, Wang, Jiangdian, Lunceford, Jared, Savage, Mary J, Juco, Jonathan, Emancipator, Kenneth

Volltext

Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study von Plimack, Elizabeth R, Dr, Bellmunt, Joaquim, MD, Gupta, Shilpa, MD, Berger, Raanan, MD, Chow, Laura Q M, MD, Juco, Jonathan, MD, Lunceford, Jared, PhD, Saraf, Sanatan, PhD, Perini, Rodolfo F, MD, O'Donnell, Peter H, MD

Volltext

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer von Garon, Edward B, Rizvi, Naiyer A, Hui, Rina, Leighl, Natasha, Balmanoukian, Ani S, Eder, Joseph Paul, Patnaik, Amita, Aggarwal, Charu, Gubens, Matthew, Horn, Leora, Carcereny, Enric, Ahn, Myung-Ju, Felip, Enriqueta, Lee, Jong-Seok, Hellmann, Matthew D, Hamid, Omid, Goldman, Jonathan W, Soria, Jean-Charles, Dolled-Filhart, Marisa, Rutledge, Ruth Z, Zhang, Jin, Lunceford, Jared K, Rangwala, Reshma, Lubiniecki, Gregory M, Roach, Charlotte, Emancipator, Kenneth, Gandhi, Leena

Volltext

Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer von Kraya, Adam A, Maxwell, Kara N, Wubbenhorst, Bradley, Wenz, Brandon M, Pluta, John, Rech, Andrew J, Dorfman, Liza M, Lunceford, Nicole, Barrett, Amanda, Mitra, Nandita, Morrissette, Jennifer J D, Feldman, Michael, Nayak, Anupma, Domchek, Susan M, Vonderheide, Robert H, Nathanson, Katherine L

Volltext

Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC von Mok, T.S.K., Lopes, G., Cho, B.C., Kowalski, D.M., Kasahara, K., Wu, Y.-L., de Castro, G., Turna, H.Z., Cristescu, R., Aurora-Garg, D., Loboda, A., Lunceford, J., Kobie, J., Ayers, M., Pietanza, M.C., Piperdi, B., Herbst, R.S.

Volltext

Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma von Haddad, Robert I, Seiwert, Tanguy Y, Chow, Laura Q M, Gupta, Shilpa, Weiss, Jared, Gluck, Iris, Eder, Joseph P, Burtness, Barbara, Tahara, Makoto, Keam, Bhumsuk, Kang, Hyunseok, Muro, Kei, Albright, Andrew, Mogg, Robin, Ayers, Mark, Huang, Lingkang, Lunceford, Jared, Cristescu, Razvan, Cheng, Jonathan, Mehra, Ranee

Volltext

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC von Garassino, Marina C., Gadgeel, Shirish, Novello, Silvia, Halmos, Balazs, Felip, Enriqueta, Speranza, Giovanna, Hui, Rina, Garon, Edward B., Horinouchi, Hidehito, Sugawara, Shunichi, Rodriguez-Abreu, Delvys, Reck, Martin, Cristescu, Razvan, Aurora-Garg, Deepti, Loboda, Andrey, Lunceford, Jared, Kobie, Julie, Ayers, Mark, Piperdi, Bilal, Pietanza, M. Catherine, Paz-Ares, Luis

Volltext

The Impact of Patient Autonomy Among Uninsured Free Clinic Patients von Panahi, Samin, Spearman, Brenda, Sundrud, Justine, Lunceford, Mason, Kamimura, Akiko

Volltext

Intraarticular injection of a Tin‐117 m radiosynoviorthesis agent in normal canine elbows causes no adverse effects von Lattimer, Jimmy C., Selting, Kimberly A., Lunceford, Joni M., Holland, James R., Simon, Jaime, Stevenson, Nigel R., Doerr, Cynthia A.

Volltext

The safety of early fresh, whole blood transfusion among severely battle injured at US Marine Corps forward surgical care facilities in Afghanistan von Auten, Jonathan D, Lunceford, Nicole L, Horton, Jaime L, Galarneau, Mike R, Galindo, Roger M, Shepps, Craig D, Zieber, Tara J, Dewing, Chris B

Volltext

Abstract CT084: Relationship between STK11 and KEAP1 mutational status and efficacy in KEYNOTE-042: pembrolizumab monotherapy versus platinum-based chemotherapy as first-line thera... von Cho, Byoung Chul, Lopes, Gilberto, Kowalski, Dariusz M., Kasahara, Kazuo, Wu, Yi-Long, Castro, Gilberto, Turna, Hande Z., Cristescu, Razvan, Aurora-Garg, Deepti, Loboda, Andrey, Lunceford, Jared, Kobie, Julie, Ayers, Mark, Pietanza, M. Catherine, Piperdi, Bilal, Mok, Tony S.

Volltext

Estimation of Survival Distributions of Treatment Policies in Two‐Stage Randomization Designs in Clinical Trials von Lunceford, Jared K., Davidian, Marie, Tsiatis, Anastasios A.

Volltext